Integrating synthetic materials with live human tissue
The CorNeat Vision lineup of biomimetic ophthalmic implants blend a novel bio-integration technology with innovative ideas to create ground-breaking solutions, which address unmet ophthalmic needs.
This technology is based on an electrospun non-woven non degradable polymer nanofabric that imitates the micro-structure of the human extracellular matrix (ECM) – the collagen mesh which provides the structural and biochemical support to surrounding cells. This ECM-like micro-structure, which is implemented as part of CorNeat Vision’s implants, stimulates cell colonization and eventually full and lifelong mechanical integration with the surrounding tissue.
On the intellectual property (IP) front, CorNeat Vision has made extensive progress over the past few years. In order to protect our innovations, we registered intellectual property for both ophthalmic and non-ophthalmic devices, leveraging CorNeat bio-integration platform technology.
As of this date, we have filed five patent applications in various jurisdictions.
Our flagship device, the CorNeat KPro (‘Keratoprosthesis and uses thereof’), was granted a patent in ten jurisdictions which include Europe, USA, China, Canada, Russia, Japan and Israel and is still pending in a few other jurisdictions.
In addition, our animal trial and other R&D activities resulted in new intellectual property. Accordingly, except for the above patent, we have four additional patent applications that have been filed.
The company continues to invest in the intellectual property front, protecting its innovative ideas and increasing its assets.